1. Introduction {#sec1}
===============

Kaposi sarcoma-associated herpesvirus (KSHV, HHV-8) is a tumorigenic γ-herpesvirus [@bib1] and provokes the development of three human malignancies. In endothelial cells, promotes Kaposi\'s sarcoma (KS) and in B-cells, two lympho-proliferative diseases: primary effusion lymphoma and the plasma cell variant of multicentric Castleman\'s disease [@bib2]. These diseases appear primarily in the context of immune deficiency and/or HIV infection, though their pathogenesis differs [@bib2]. KS is a multifocal, highly vascular tumor; cells display features of activated endothelial cells, and develops on the lower extremities, mucous membranes or internal organs \[[@bib1], [@bib3]\]. KSHV encodes several oncogenic viral homologues of host proteins with the potential to stimulate cell survival, proliferation, immune evasion and angiogenesis \[[@bib4], [@bib5], [@bib6]\]. Among them, the viral G protein-coupled receptor (vGPCR) has shown to transform endothelial cells due to its pro-angiogenic capacity promoting tumor growth \[[@bib3], [@bib4], [@bib5], [@bib7]\]. The vGPCR is encoded by the ORF74, and presents homology with CXCR1 and CXCR2, receptors of IL-8 and Gro-α in the host \[[@bib3], [@bib8], [@bib9]\]. This viral receptor is constitutively active because of the presence of structural changes within its DRY domain in the second intra-cytoplasmic loop, which is highly conserved in GPCRs \[[@bib4], [@bib10]\]. Among the multiple intracellular pathways stimulated by vGPCR, the Akt/mTOR signaling axis represents one of the most prominent oncogenic mechanism activated, an event that has been revealed by animal models of KS \[[@bib7], [@bib11]\]. vGPCR activates Akt/mTOR by stimulating PI3K through βγ-subunits and by an autocrine manner up-regulating VEGFR2/KDR expression and VEGF release \[[@bib4], [@bib12]\]. Moreover, PI3Kγ has been identified as the activator of Akt/mTOR in endoth elial cells expressing vGPCR and also to mediate sarcomagenesis *in vivo* [@bib13].

It is well documented the important role of the PI3K/Akt pathway in cell growth, proliferation, survival and metabolism [@bib14]. In cancer cells, it plays a central role in aerobic glycolytic reprogramming, tumor growth, and survival [@bib15]. mTOR, a major intracellular repressor of autophagy, is positively regulated by the PI3K/Akt pathway [@bib16].

Autophagy is a mechanism that mediates the sequestration of cytoplasmic material in autophagosomes, double membrane vesicles, that in turn fuse to lysosomes for degradation \[[@bib17], [@bib18]\]. Autophagy not only occurs under normal conditions to maintain cell homeostasis, but also during unfavorable conditions \[[@bib16], [@bib19]\]. In neoplastic cells, autophagy constitutes a mean to face intracellular and environmental stress, thus favoring tumor progression [@bib18]. There are several autophagy inducers that operate in general activating cascades of signal transduction that result in mTOR complex 1 inhibition \[[@bib20], [@bib21]\]. Among other effects, this allows the activation of proteins that are crucial in autophagosomes formation, such as ULK-1, ATG13 and Beclin-1 (BECN1) \[[@bib18],[@bib22]\]. Autophagy is governed by a series of Atg genes \[[@bib16], [@bib18], [@bib23]\]. Although all ATG8 proteins are indispensable for autophagy, LC3 acts as the major ATG8 protein to induce autophagy; thus, increased levels of LC3-II proteins in autophagosome membranes are important biomarkers of autophagy \[[@bib16], [@bib24]\].

The active form of vitamin D, 1α, 25 (OH)~2~-vitamin D~3~ (1α,25(OH)~2~D~3~) or calcitriol plays an important role in maintaining calcium homeostasis. Most of 1α,25(OH)~2~D~3~ actions are mediated through the vitamin D receptor (VDR), a member of the nuclear receptor superfamily [@bib25]. In addition to its classical effects, 1α,25(OH)~2~D~3~ has antineoplastic and anti-inflammatory effects in several tumor types. The anti-proliferative, pro-apoptotic and pro-differentiation action of the metabolite has been demonstrated in various malignant cells and also in animal models where it retards tumor growth \[[@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31]\]. We have previously revealed that 1α,25(OH)~2~D~3~ or its less-calcemic analog TX 527 inhibits the proliferation of endothelial cells expressing vGPCR *in vitro* and *in vivo* [@bib32], down regulates NF-ĸB pathway, highly activated by the viral receptor \[[@bib33], [@bib34]\], and induces apoptosis in a VDR dependent manner \[[@bib35], [@bib36]\]. Since there is evidence indicating that 1α,25(OH)~2~D~3~ triggers autophagy as part of its mechanism of action in certain tumor cells \[[@bib37], [@bib38], [@bib39]\], we further explore whether 1α,25(OH)~2~D~3~ or TX 527 induces autophagy in endothelial cells expressing vGPCR by inhibiting PI3K/Akt/mTOR pathway.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Vitamin D analog TX 527 \[19-nor-14,20-bisepi-23-yne-1,25(OH)~2~D~3~\] was originally synthesized by M. Vandewalle and P. De Clercq (University of Ghent, Ghent, Belgium) and provided by Théramex (Monaco). Immobilon P (polyvinylidenedifluoride; PVDF) membranes, 1α,25(OH)~2~D~3~, the antibiotic G418 and LY294002 were from Sigma-Aldrich (St. Louis, MO, USA). Puromycin supplied by Invivogen (San Diego, CA, USA). The antibodies used were rabbit monoclonal anti-p-Akt, anti-Akt, anti-MEKα (Cell Signaling Technology, Danvers, MA, USA) and anti-Tubulin (Thermo Fisher Scientific Inc., Waltham, MA, USA); mouse monoclonal anti-LC3, anti-BECN1, anti-p-mTOR, and anti-mTOR, goat polyclonal Lamin B and secondary antibodies anti-rabbit, anti-mouse and anti-goat (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Roche Applied Science supplied high Pure RNA Isolation Kit (Indianapolis, IN, USA). High Capacity cDNA RT and SYBR Green PCR Master Mix reagent (Applied Biosystems) were acquired from Thermofisher (Thermofisher, Buenos Aires, AR). GAPDH primer was from Invitrogen^TM^ (Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA, USA) and BECN1 primer was obtained by Eurogentec (Serain, Belgium). The inhibitor of flux autophagy, Chloroquine, was kindly provided by Dr. Daniel Grasso (IBIMOL Universidad de Buenos Aires -- CONICET).

2.2. Cell lines and transfections {#sec2.2}
---------------------------------

SV-40 immortalized murine endothelial cells (SVEC) stably expressing the vGPCR (full-length) were used as experimental model of KS \[[@bib3], [@bib32]\]. Cells were cultured and selected with 500 μg mL^−1^ G418 [@bib3]. Stable vGPCR endothelial cells targeted with small hairpin RNA against mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl) were obtained before by transduction of lentiviral particles generated in HEK293T cells and selected with 2 μg mL^−1^ puromycin [@bib32].

2.3. Proliferation assays {#sec2.3}
-------------------------

vGPCR cells were seeded in 24-well plates, at 6000 cells per well. After overnight growth, the cells were starved for 24 h and then treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01%, ethanol) in triplicate in DMEM 2% fetal bovine serum (FBS) for 48 h. Cells were then harvested and counted in a Neubauer chamber using 0,4% of trypan blue stain to distinguish living from died cells according to trypan blue exclusion test [@bib40] In addition, proliferation was measured using CellTiter 96® AQueous one solution cell proliferation assay containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) in 96-well plates as we have previously reported [@bib34].

2.4. SDS-PAGE and Western blot {#sec2.4}
------------------------------

Whole protein lysates were prepared as previously reported by us [@bib33] and protein content was determined by the Bradford procedure [@bib41]. Proteins were resolved (with SDS--PAGE) and transferred to PVDF membranes followed by Western blot analyzes [@bib41]. Membranes were blocked and incubated with primary antibodies \[anti: p-Akt (1:1000), Akt (1:1000), Tubulin (1:1000), MEKα (1:1000), Lamin B (1:1000), BECN1 (1:500), LC3 (1:500), p-mTOR (1:500), mTOR (1:500)\] diluted in TBST buffer (0.1% tween) overnight at 4 °C. After three washes in TBST buffer, membranes were incubated with the corresponding secondary antibodies (1:5000) diluted in TBST buffer (2.5% dry milk) 1 h at room temperature. Later, after three washes in TBST buffer, blot signal was detected using an enhanced chemiluminescence kit according to the manufacturer\'s instructions (Amersham ECL Western Blotting Detection Kit, GE Healthcare, Buenos Aires, AR). Images were scanned and quantified using ImageJ software, developed at the National Institutes of Health.

2.5. Subcellular fractionation {#sec2.5}
------------------------------

vGPCR cells were scrapped in ice-cold Tris-EDTA-Sucrose (TES) buffer (50 mmol L^−1^Tris-HCl pH 7.4, 1 mmol L^−1^ EDTA, 250 mmol L^−1^ sucrose, 1 mmol L^−1^ DTT) containing proteases inhibitors (0.5 mmol L^−1^ PMSF, 20 μg mL^−1^ aprotinin and 20 μg mL^−1^ leupeptin). Lysates were passed through a 25 G needle 10 times using a 1 mL syringe and left on ice for 20 min. Then, homogenate was centrifuged at 100 g for 5 min to eliminate debris; supernatant was further centrifuged at 1500 g for 20 min to sediment the nuclear fraction. The supernatant was further centrifuged at 14000 g for 20 min to pellet mitochondria. The remaining supernatant was collected as cytosol fraction [@bib42]*.* Protein concentration from each fraction was estimated by the Bradford method. Goat anti-Lamin B and rabbit anti-MEKα antibodies were employed for the immunodetection of the nuclear protein marker Lamin B and the cytosol protein marker MEKα, in the different fractions.

2.6. Quantitative real-time PCR {#sec2.6}
-------------------------------

Total RNA for real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis was isolated using the High Pure RNA Isolation Kit (Roche) [@bib34]. Total RNA (1 μg) was reverse transcribed using the kit High Capacity cDNA RT (Applied Biosystems, Thermofisher, Buenos Aires, AR) and qRT-PCR reactions were achieved on the resulting cDNA (5--10 ng) in an ABI 7500 Real Time PCR system (Applied Biosystems, CA, USA) using specific primers to detect A20 and BECN1 levels and GAPDH to normalize gene expression. Primers used for amplification were: murine *Gapdh,* forward 5′-AAGGTGAAGGTCGGAGTC-3′, reverse 5′-GAAGATGGTGATGGGATTTC-3′; murine *Becn1,* forward 5′-GGACAAGCTCAAGAAAACCAATG-3′, reverse 5′-TGTCCGCTGTGCCAGATG-3'; murine *A20* forward 5′-CATGAAGCAAGAAGAACGGAAGA-3′, reverse 5′-GAGGCCCGGGCACATT-3'. Reactions were carried out using the SYBR Green PCR Master Mix reagent (Applied Biosystems). Gene expression was then analyzed by 2-delta delta Ct method [@bib43].

2.7. Statistical analysis {#sec2.7}
-------------------------

Data are shown as means ±aSD. Data from control and treated conditions obtained by qRT-PCR or Western blot were analyzed by the two tailed t-test. A *p* value \<0.01 (\*\*) and \<0.05 (\*) were considered statistically significant. Data from more than two conditions were analyzed by one-way ANOVA followed by Bonferroni test. Different superscript letters indicate significant differences at p \< 0.05 or p \< 0.01.

3. Results {#sec3}
==========

3.1. Akt inactivation reduces vGPCR cell number likewise 1α,25(OH)~2~D~3~ or TX 527 {#sec3.1}
-----------------------------------------------------------------------------------

In a cellular model of KS, Martin and colleagues reported that vGPCR expression in endothelial cells strongly stimulates Akt (pAkt S473) and mTOR, event that was accompanied by morphological changes with an increase in cell size and a longer survival of cells after growth factors deprivation [@bib44]. We first investigated whether 1α,25(OH)~2~D~3~ or TX 527 exerts its anti-proliferative effect through the regulation of Akt in endothelial cells transformed by vGPCR. To that end, vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or 10 μM of LY294002 (PI3K/Akt inhibitor) or vehicle (0.01% ethanol) for 48 h. After treatment, micrographs of each condition were taken in a phase contrast microscope ([Fig. 1](#fig1){ref-type="fig"}A). To measure cell proliferation, cells were collected, counted in a Neubauer chamber and, finally, living cells percentage was calculated according to control cells ([Fig. 1](#fig1){ref-type="fig"}B). As can be seen from [Fig. 1](#fig1){ref-type="fig"}, vGPCR cells number decreased significantly in presence of LY294002 similar to 1α,25(OH)~2~D~3~ or TX 527. Furthermore, these results were confirmed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay ([Fig. 1](#fig1){ref-type="fig"}C). In addition, these effects were accompanied by cellular morphological changes, observed by light field microscopy showed abnormal round cells and condensed nuclei, presuming that Akt inhibition is part of both compounds antineoplastic action. To evaluate this possibility, Akt phosphorylation state was studied as a measure of its activity in dose and time response studies. vGPCR cells were treated with increasing concentrations of 1α,25(OH)~2~D~3~ or TX 527 (0.1--100 nM) or vehicle (0.01% ethanol) for 48 h or with 10 nM of each compound for different times (12--72 h). Then, Akt protein levels and its phosphorylation state were analyzed by Western blot. The results presented in [Fig. 2](#fig2){ref-type="fig"}A show that both compounds caused a significant decrease in Akt phosphorylation without modifying its total protein levels in a dose-dependent manner. In addition, time-response studies revealed that Akt phosphorylation significantly decreased after 12--72 h of 1α,25(OH)~2~D~3~ or TX 527 treatment ([Fig. 2](#fig2){ref-type="fig"}B).Fig. 1vGPCR cell growth inhibition by LY294002 and VDR agonists. vGPCR cells were seeded and treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% ethanol) or 10 μM of LY294002 (LY) for 48 h. A) Representative micrographs obtained by phase contrast microscopy, bar: 30 μm, magnification 200x. B) Cells were counted in Neubauer chamber or C) in parallel experiments, MTS assay was performed, and the results, from at least three independent experiments, were presented in bar graphs. The statistical analysis was performed by one-way ANOVA followed by the Bonferroni test. Significant differences are indicated by different letters (p \< 0.01).Fig. 1Fig. 21α,25(OH)~2~D~3~ or TX 527 decreases Akt phosphorylation in a dose and time dependent manner. vGPCR cells were treated with A) increasing concentrations of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 (0--100 nM), or vehicle (0.01% ethanol) for 48 h or B) 10 nM of 1,25D or TX 527 or vehicle (0.01% ethanol) at different times (12--72 h). Total and phosphorylated Akt was analyzed by Western blot and Tubulin was used as loading control. In A and B a representative blots of at least three independent experiments and their quantification in bar graphs are shown. The statistical analysis in A was performed by one-way ANOVA followed by the Bonferroni test. Different letters indicate significant differences between conditions with p \< 0.01; and in B the effect of each treatment (1,25D or TX 527) was compared with control at each time point by the Student\'s t test (\*p \< 0.05; \*\*p \< 0.01). Full, non-adjusted and uncropped images of [Fig. 2](#fig2){ref-type="fig"} are shown in suppl. material.Fig. 2

3.2. 1α,25(OH)~2~D~3~ inhibits the translocation of phosphorylated Akt to the nucleus {#sec3.2}
-------------------------------------------------------------------------------------

To inquire into 1α,25(OH)~2~D~3~ mechanism of action on Akt regulation, we next investigated whether the observed decrease in Akt phosphorylation affects its subcellular location. For this, vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or vehicle (0.01% ethanol) for 48 h. Then, cells were collected, homogenized in TES buffer and a subcellular fractionation was performed to obtain the nuclear and cytosol fraction. Phosphorylated and total Akt levels were analyzed by Western blot and the purity of the fractions was determined through specific markers, Lamin B for nucleus and MEKα for cytosol. The results in [Fig. 3](#fig3){ref-type="fig"} indicate that 1α,25(OH)~2~D~3~ provoked a significant decrease in phosphorylated Akt in the nucleus respect to cytosol ([Fig. 3](#fig3){ref-type="fig"}B) suggesting the attenuation of Akt activity in the nucleus due to 1α,25(OH)~2~D~3~ treatment and its translocation to cytosol ([Fig. 3](#fig3){ref-type="fig"}C).Fig. 3Subcellular localization of Akt by 1α,25(OH)~2~D~3~. vGPCR cells were cultured and treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or vehicle (0.01% ethanol) for 48 h. Then, cells were collected in TES buffer and a subcellular fractionation was performed to obtain the nuclear fraction (N) and the cytosol (C). The levels of phosphorylated and total Akt and specific markers for each fraction, MEKα for C and Lamin B for N, were analyzed by Western blot. Representative blots of three independent experiments are shown and their quantification is represented in a bar graph where the radio of p-Akt/Total is expressed in N with respect to C (N: C). Statistical analysis was performed by the Student\'s t-test, significant differences between the 1,25D and control were evaluated (\*p \< 0.05). Full, non-adjusted and uncropped images of [Fig. 3](#fig2){ref-type="fig"} are shown in suppl. material.Fig. 3

3.3. 1α,25(OH)~2~D~3~ or TX 527 decreases Akt activation by a VDR dependent mechanism {#sec3.3}
-------------------------------------------------------------------------------------

Like other steroid hormones, 1α,25(OH)~2~D~3~ exerts its effect through a genomic mechanism mediated by VDR and a non-genomic one of rapid responses initiated in the membrane [@bib45]. Therefore, we investigated whether VDR knockdown affects Akt activation. We used the vGPCR-shVDR cell line where VDR expression was silenced by a short hairpin against mouse VDR, or the control line, vGPCR-shctrl. Both cell lines were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% ethanol) for 48 h ([Fig. 4](#fig4){ref-type="fig"}A). First, VDR knockdown was verified as we have reported before (Suppl. Material) (Gonzalez Pardo et al., 2010, Gonzalez Pardo et al 2014). Second, as it was previously observed, 1α,25(OH)~2~D~3~ or TX 527 significantly decreased Akt phosphorylation after 48 h of treatment, whereas when VDR expression was knockdown, Akt phosphorylation was not affected by both agonists.Fig. 4Decreased Akt phosphorylation is VDR and NF-ĸB dependent. A) vGPCR-shctrl (shctrl) and vGPCR-shVDR (shVDR) cells were cultured and treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% ethanol) for 48 h. B) vGPCR cells were treated with Bortezomib (0.25--1 nM) or vehicle (DMSO, 0.1%) for 24 h. Phosphorylated and total Akt levels were evaluated by Western blot and Tubulin was used as loading control. Representative blots of at least three independent experiments and their quantification plotted on a bar graph are shown. Full, non-adjusted and uncropped images and VDR silencing are shown in suppl. material. The statistical differences were analyzed by one-way ANOVA followed by the Bonferroni test. Different letters indicate significant differences (p \< 0.05).Fig. 4

3.4. Inhibition of NF-ĸB pathway by Bortezomib decreases Akt phosphorylation like VDR agonists {#sec3.4}
----------------------------------------------------------------------------------------------

Results from our group have revealed that the inhibition of the NF-ĸB pathway by Bortezomib plays an important role in the regulation of the cell cycle [@bib34]. This regulation could be attributed to an inhibition of Akt activity by NF-κB. To evaluate this possibility, vGPCR cells were treated with increasing concentrations of Bortezomib (0.25--1 nM) or vehicle (0.1% DMSO) for 24 h and then Akt phosphorylation state was assessed by Western blot. The results presented in [Fig. 4](#fig4){ref-type="fig"}B indicate that Bortezomib induced a significant decrease of Akt phosphorylation in a dose-dependent manner; however, at the highest concentration of 1 nM, Akt phosphorylation tended to increase, suggesting that activated Akt contribute to activate cell survival and counteract the apoptosis induced by Bortezomib.

3.5. A20 is highly expressed in vGPCR cells and is down-regulated by 1α,25(OH)~2~D~3~ or TX 527 {#sec3.5}
-----------------------------------------------------------------------------------------------

TNFAIP3/A20 is an ubiquitin-editing enzyme and a direct NF-κB target gene that is thought to be a negative regulator of autophagy in some cell lines [@bib46]. It has been proposed that A20 expression limits TLR4-induced autophagy by deubiquitinating TRAF6 and BECN1 [@bib47]. In earlier studies, we have demonstrated that NF-κB is highly expressed in vGPCR cells and is down regulated by VDR agonists \[[@bib33], [@bib34]\]. Here, we investigated A20 expression in SVEC and vGPCR cells and whether it was regulated by NF-κB inhibitor Bortezomib or VDR agonists as part of their mechanism of action ([Fig. 5](#fig5){ref-type="fig"}). First, SVEC and vGPCR cells were cultured and treated with Bortezomib at different concentrations or vehicle (DMSO, 0.1%) during 24 h and then A20 protein levels were analyzed by Western blot. According to [Fig. 5](#fig5){ref-type="fig"}A, A20 was barely expressed in SVEC cells whereas was found highly expressed in vGPCR and down-regulated by Bortezomib in a dose-response manner. Secondly, dose (0.1--100 nM) ([Fig. 6](#fig6){ref-type="fig"}) and time response studies (10 nM, 3--72 h) were carried out to investigate the role of 1α,25(OH)~2~D~3~ or TX 527 on A20 expression ([Fig. 5](#fig5){ref-type="fig"}B and C). The results of these studies indicated that both compounds decreased A20 protein expression in dose and time studies, though the effect was reverted at 100 nM of both compounds. Moreover, A20 mRNA was rapidly decreased at 3 h and sustained up to 72 h ([Fig. 5](#fig5){ref-type="fig"}B); response that was reflected in a decrement in A20 protein expression (12--72 h) analyzed by Western blot ([Fig. 5](#fig5){ref-type="fig"}C). In addition, this effect was found to be VDR dependent ([Fig. 7](#fig7){ref-type="fig"}).Fig. 5A20 is regulated by Bortezomib and VDR agonists in vGPCR cells. A) SVEC and vGPCR cells were treated with Bortezomib (0.25--1 nM) or vehicle (DMSO, 0.1%) for 24 h A20 protein levels were tested by Western blot and Tubulin was used as loading control. Representative blots of at least three independent experiments and their quantification plotted on a bar graph are shown. The statistical differences were analyzed by one-way ANOVA followed by the Bonferroni test. Different letters indicate significant differences (p \< 0.05). vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% ethanol) at different times to evaluate A20 gene (3--72 h) and protein (12--72 h) expression. B) Total RNA was isolated and A20 expression was evaluated on the resulting cDNA and the values obtained were normalized with GAPDH as shown in the bar graph. C) Protein levels of A20 and Tubulin were analyzed by Western blot. Representative blots and their quantification of at least three independent experiments are shown in a bar graph. Significant differences between 1,25D or TX527 and their respective control at each time were analyzed by the Student\'s t test (\*p \< 0.05, \*\*p \< 0.01). Full, non-adjusted and uncropped images are shown in suppl. Material.Fig. 5Fig. 61α,25(OH)~2~D~3~ or TX 527 decreased A20 protein levels in a dose dependent manner in vGPCR cells. vGPCR cells were treated with increasing concentrations of 1α,25(OH)~2~D~3~ or TX 527 (0--100 nM) or vehicle (0.01 % ethanol) for 48 h. Cell lysates were subject to Western blot analysis with anti-A20 and anti-Tubulin antibodies. Representative blots and quantification of at least three independent experiments are shown. Full, non-adjusted and uncropped images are shown in suppl. Material. Protein bands quantification were achieved by densitometry and then represented in bar graphs as the radio between A20 and Tubulin referred to vehicle. The statistical analysis of the results was carried out by one way-ANOVA followed by Bonferroni test. Different letters indicate statistical significances at \*p \< 0.01.Fig. 6Fig. 7A20 downregulation by VDR agonists is VDR dependent. Stable vGPCR cells targeted with small hairpin RNA against mouse VDR (vGPCR-shVDR) or control (vGPCR-shctrl) were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% ethanol) for 48 h. Total protein from cells lysates were subject to Western blot analysis with anti-A20 and anti-Tubulin antibodies. A representative Western blot from four independent experiments is shown; full, non-adjusted and uncropped images are shown in suppl. Material. A20 protein bands were quantified, normalized using Tubulin, and represented in a bar graph. Significant differences between control (vehicle) and stimulated cells were analyzed by one-way ANOVA followed by Bonferroni test, p \< 0.01.Fig. 7

3.6. 1α,25(OH)~2~D~3~ or TX 527 induces changes in BECN1 expression {#sec3.6}
-------------------------------------------------------------------

BECN1 is a protein that is expressed in many human tissues and there is evidence suggesting that the transcription factor E2F and NF-κB are involved in the regulation of its expression [@bib48]. Wang and colleagues demonstrated that 1α,25(OH)~2~D~3~ induces autophagy in human myeloid leukemia cells by up-regulation of BECN1 expression and inhibition of mTOR phosphorylation [@bib37]. We next evaluated whether BECN1 is regulated by both VDR agonists. First, vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% ethanol) at different times ([Fig. 8](#fig8){ref-type="fig"}). BECN1 mRNA levels were analyzed in time-response studies (6--48 h) by qRT-PCR ([Fig. 8](#fig8){ref-type="fig"}A). Treatment with 1α,25(OH)~2~D~3~ caused a significant decrease in BECN1 mRNA levels at 12 and 24 h, whereas at 48 h, a highly significant increase was observed. In contrast, TX 527 caused a significant increase in BECN1 mRNA levels at 12 and 24 h, and a highly significant decrease at 48 h. Secondly; we investigated whether changes in BECN1 mRNA expression were reflected into changes in its protein levels in parallel experiments ([Fig. 8](#fig8){ref-type="fig"}B). The quantification of the results obtained reveal that 1α,25(OH)~2~D~3~ induced a significant increase in BECN1 protein levels at 24 h and a decrease at 12 and 48 h; meanwhile, TX 527 induced a significant increase in BECN1 in a time dependent manner between 12 to 48 h. Discrepancies observed between transcript and protein levels at same time point could be related with regulatory mechanisms occurring after mRNA is synthetized and protein abundance regulation.Fig. 81α,25(OH)~2~D~3~ or TX 527 induces changes in BECN1 expression. vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% ethanol) for different times to evaluate BECN1 gene (6--48 h) and protein (6--72 h) expression. A) Total RNA was isolated and BECN1 expression was evaluated on the resulting cDNA and the values obtained were normalized with GAPDH as shown in the bar graph. B) Protein levels of BECN1 and Tubulin were analyzed by Western blot. Representative blots and their quantification of at least three independent experiments are shown in a bar graph; full, non-adjusted and uncropped images are shown in suppl. Material. Significant differences between 1,25D or TX527 and their respective control at each time were analyzed by Student\'s t test (\*p \< 0.05, \*\*p \< 0.01).Fig. 8

3.7. 1α,25(OH)~2~D~3~ or TX 527 inhibits mTOR phosphorylation and induces autophagy by a PI3K/Akt dependent mechanism {#sec3.7}
---------------------------------------------------------------------------------------------------------------------

As outlined in the introduction, autophagy is governed by a series of Atg genes, being LC3 an important biomarker of autophagy. During the process of autophagosome development, ATG8 proteins are specifically cleaved to expose a glycine residue to become 'form I' proteins, then, this glycine residue is then conjugated to phosphatidylethanolamine, changing into 'form II' proteins [@bib23]. Fleet and collaborators reported that 1α,25(OH)~2~D~3~ suppresses mTOR in leukemia cells contributing to the development of autophagy [@bib49]. Next, mTOR phosphorylation status was evaluated as a measure of its activity and LC3-II proteins levels as a measure of autophagy. vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% ethanol) for 48 h ([Fig. 9](#fig9){ref-type="fig"}A). To evaluate the participation of the PI3K/Akt/mTOR axis in autophagy triggered by 1α,25(OH)~2~D~3~, vGPCR cells were incubated with 10 μM of LY294002 or vehicle (0.01% ethanol) during 15 min prior to 1α,25(OH)~2~D~3~ treatment (10 nM) or vehicle (0.01% ethanol) for 48 h ([Fig. 9](#fig9){ref-type="fig"}B). The results shown in [Fig. 9](#fig9){ref-type="fig"}A indicate that 1α,25(OH)~2~D~3~ or TX 527 decreased mTOR phosphorylation without causing changes in its total protein levels. In addition, autophagy was induced by 1α,25(OH)~2~D~3~ ([Fig. 9](#fig9){ref-type="fig"}B) and in presence of LY294002, LC3-II levels were significant increased comparable to 1α,25(OH)~2~D~3~ treatment. Moreover, LC3-II levels showed no greater increase when LY294002 was combined with 1α,25(OH)~2~D~3~.Fig. 91α,25(OH)~2~D~3~ or TX 527 decreases mTOR phosphorylation and induces autophagy. vGPCR cells were incubated with 10 μM of LY294002 (LY) or vehicle (0.01% ethanol) for 15 min prior to 1α,25(OH)~2~D~3~ (10 nM) or vehicle (0.01% ethanol). The protein levels of phosphorylated and total mTOR (A) or LC3 (B) were analyzed by Western blot using Tubulin as loading control. Representative blots are shown and the quantification of six independent experiments is represented in bar graphs. Significant differences between conditions were evaluated in A) by one-way ANOVA followed by the Bonferroni test (p \< 0.05) or B) significant differences between pairs of conditions were evaluated through the Student t test (\*p \< 0.05, \*\*p \< 0.01, n. s: not significant). Full, non-adjusted and uncropped images are shown in suppl. Material.Fig. 9

3.8. Inhibition of autophagy flow with Chloroquine induces LC3 proteins levels like VDR agonists {#sec3.8}
------------------------------------------------------------------------------------------------

Because the accumulation of autophagosomes is toxic to cells \[[@bib50], [@bib51]\], the blockage of autophagosomes degradation with Chloroquine after 1α,25(OH)~2~D~3~ or TX 527 treatment could be detrimental to vGPCR cells survival and this would allow us to confirm autophagy induction. To test this hypothesis, vGPCR cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% of ethanol) for 48 h and 30 min prior to finish VDR agonists treatments, Chloroquine (1 μM, CQ) was added to inhibit autophagy flow by decreasing the autophagosome-lysosome fusion \[[@bib52], [@bib53], [@bib54]\]. In presence of CQ, LC3-II levels were comparable to control condition and in combination with 1α,25(OH)~2~D~3~ did not increase, whereas with TX 527 the effect observed was enhanced ([Fig. 10](#fig10){ref-type="fig"}A). We also investigated whether VDR participates in LC3-II induction by both VDR agonists. For this, vGPCR-shVDR or vGPCR-shctrl cells were treated with 10 nM of 1α,25(OH)~2~D~3~ or TX 527 or vehicle (0.01% ethanol) for 48 h ([Fig. 10](#fig10){ref-type="fig"}B). The results showed that the significant increase in LC3-II amount was suppressed when VDR expression was knockdown indicating that both, 1α,25(OH)~2~D~3~ and TX 527, exert their actions through a VDR dependent mechanism of action.Fig. 10Inhibition of autophagy flow with Chloroquine induces LC3 levels and is VDR dependent. A) Cells were treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% of ethanol) for 48 h and 30 min before the end of VDR agonists treatments, 1 μM of Chloroquine (CQ) was added. B) vGPCR-shctrl (shctrl) and vGPCR-shVDR (shVDR) cells were cultured and treated with 10 nM of 1α,25(OH)~2~D~3~ (1,25D) or TX 527 or vehicle (0.01% ethanol) for 48 h LC3 and Tubulin levels were evaluated by Western blot. A representative blot of three independent experiments is shown, and the quantification is represented in bar graphs. Full, non-adjusted and uncropped images are shown in suppl. Material. In A) significant differences between conditions were evaluated by Student\'s t test between 1,25D or TX 527 or CQ and ctrl (\*p \< 0.05, \*\*p \< 0.01) whereas in B) significant differences between control (vehicle) and agonists were analyzed by one-way ANOVA, followed by the Bonferroni test. Significant differences between conditions are indicated by different letters (p \< 0.05).Fig. 10

4. Discussion {#sec4}
=============

Apoptosis and autophagy are evolutionarily conserved processes that regulate cell fate. Both processes are important for the development and normal physiology of tissues and have been found to be regulated in a wide range of diseases [@bib55]. It is well known that infection with KSHV induces the expression of viral proteins that contribute to the development of different malignancies. It has been observed that vFLIP, for example, suppresses apoptosis and autophagy favoring cell survival. On the other hand, infection with KSHV activates mTOR, a negative regulator of autophagy process and an important molecule for cell proliferation, modulation and angiogenesis [@bib5]. Autophagy is induced by several forms of cellular stress including starvation, hypoxia and infection, as well as can be induced by drugs used in therapy against cancer and other diseases \[[@bib44], [@bib56]\]. Numerous studies have shown that 1α,25(OH)~2~D~3~ has the ability to induce autophagy in different cell types. For instance, in lymphoma cells and breast cancer, 1α,25(OH)~2~D~3~ and its analog EB1089 showed a cytotoxic effect triggering cell death by a caspase independent mechanism, characterized by an increase in lysosomal activity [@bib38]. In addition, 1α,25(OH)~2~D~3~ has shown to induce autophagy in myeloid leukemia and in luminal breast cancer cells \[[@bib37], [@bib39]\]. Also, 1α,25(OH)~2~D~3~-induced autophagy may require a complex interplay with CDK inhibitors, for instance, in p19 deficient SCC25 cells 1α,25(OH)~2~D~3~ autophagy induction can be suppressed by p27 suppression [@bib57]. Moreover, studies in breast cancer cells revealed that the combined treatment of 1α,25(OH)~2~D~3~ plus ionizing radiation induces cytotoxic autophagy [@bib58]. This effect of 1α,25(OH)~2~D~3~ is not limited to cancer cells. In this regard, concentrations at picomolar order of the metabolite have shown to induce autophagy in primary monocytes and macrophages suggesting that it could stimulate autophagy in normal physiological conditions [@bib59]. 1α,25(OH)~2~D~3~ may prevent human umbilical vein endothelial cells death through modulation of the interplay between apoptosis and autophagy. This effect is obtained by inhibiting superoxide anion generation, maintaining mitochondria function and cell viability, activating survival kinases, and inducing nitric oxide production [@bib60]. In this work, we have obtained evidence indicating that inhibition of PI3K/Akt pathway causes a decrease in cell proliferation comparable to VDR agonists in vGPCR cells. As previously mentioned, Akt plays a crucial role in the development of KS \[[@bib7], [@bib11]\]. Moreover, we found that both VDR agonists reduce Akt phosphorylation state through a VDR dependent mechanism and decreases its translocation to the nucleus. In support of these results, recent findings *in vitro* and *in vivo* studies in breast cancer models showed an active role of 1α,25(OH)~2~D~3~ in the induction of autophagy by a mechanism that involves VDR participation [@bib39]. Wu and colleagues demonstrated that the absence of intestinal epithelial VDR affects microbial assemblage and increases susceptibility to dextran sulfate sodium-induced colitis. Also, VDR down regulates ATG16L1 and lysozyme expression, and impairs antimicrobial function and autophagy of Paneth cells [@bib61]. Similar to VDR agonists, Bortezomib caused a decrease in Akt phosphorylation in a dose-dependent manner. In support of this result, studies in different hepatocarcinoma cell lines showed that Bortezomib decreases Akt phosphorylation/activation preceding cell death by apoptosis [@bib62]. Furthermore, in SK-BR-3 cells, a marked inhibition of EGFR, HER-2, and Akt phosphorylation was observed at a clinically relevant concentration of Bortezomib [@bib63]. In this work, we have also obtained evidence that 1α,25(OH)~2~D~3~ or TX 527 decreased mTOR phosphorylation and induced autophagy revealed by an increment in LC3-II marker, an event that is triggered by inactivation of PI3K/Akt pathway. In agreement with this result, *in vivo* studies showed that treatment with Hesperidin attenuates myocardial lesions caused by ischemia/reperfusion by suppressing autophagy through activation of the PI3K/Akt/mTOR pathway [@bib64]. Also, Yang and collaborators presented data suggesting that the protective role of vitamin D in mouse liver ischemia/reperfusion injury is autophagy-dependent, which is regulated by both MEK/ERK and PTEN/PI3K/Akt/mTOR pathway [@bib65].

Many autophagy regulators are substrates for ubiquitin E3 ligases or deubiquitinating enzymes, therefore ubiquitination modifications of these autophagy regulators result in autophagy induction or termination [@bib66]. As was mentioned before, TNFAIP3/A20 is a direct NF-κB target gene, and A20 expression could limit autophagy by regulating BECN1. We have found that A20 is highly expressed in vGPCR and its expression is down-regulated by the inhibition of NF-κB with Bortezomib or VDR agonists in a VDR dependent manner. We have also found that BECN1 is temporarily modulated by VDR agonists. Although BECN1 mRNA and protein levels vary, when it is increased, it would regulate the initial steps of autophagy. Autophagy and apoptosis can be trigger by common stimuli and signaling pathways leading to a balance between both processes. It has been described that BECN1 is involved in these processes. On one hand, BECN1 participates in autophagosome formation upon autophagy stimuli, on the other, it can be cleaved by caspases, translocate to the mitochondria, and participate in apoptosis induction [@bib48]. We have shown in previous studies that apoptosis is induced by VDR agonists by a caspase-3 dependent mechanism in vGPCR cells [@bib35], so that, the differences observed in BECN1 levels could be explained by the fact that this protein could cooperate in both processes to contribute to cell death. In support of our results, BECN1has shown to participate in the activation of apoptosis and autophagy pathways induced by EB1089, a synthetic analog of 1α,25(OH)~2~D~3~, in breast cancer cells (MCF-7) [@bib67]. On the other hand, an increase in BECN1 levels, triggers differentiation, inhibits apoptosis and induces autophagy in myeloid leukemia cells after 1α,25(OH)~2~D~3~ treatment [@bib37].

5. Conclusions {#sec5}
==============

Taken together, these results demonstrate that 1α,25(OH)~2~D~3~ or TX 527 induces autophagy in endothelial cells expressing vGPCR through the inactivation of PI3K/Akt/mTOR axis by a VDR-dependent mechanism.
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